Headquartered in New Haven, CT, Achillion is a leading-edge pharmaceutical company advancing multiple candidates with proven mechanisms for the treatment of HCV. Click here for more information about Achillion's ongoing clinical trials.
Hepatitis C is a worldwide epidemic affecting more than 170 million individuals. Click to learn more about this disease.
No upcoming events at this time.
Achillion Reports 2013 Fourth Quarter and Year-End Financial Results
Achillion to Present at Two Upcoming Investor Conferences